Gilead Sciences (GILD) Convertible Debt (2009 - 2010)
Gilead Sciences (GILD) posted Convertible Debt of $2.8 billion for Q4 2010, up 0.7% quarter-over-quarter from $2.8 billion in Q3 2010, and up 145.67% year-on-year from $1.2 billion in Q4 2009.
Gilead Sciences (GILD) Convertible Debt (2009 - 2010) Analysis & Trends
Gilead Sciences (GILD) has reported Convertible Debt for 2 consecutive years, with $2.8 billion the latest figure, recorded in Q4 2010.
- Convertible Debt for Q4 2010 came in at $2.8 billion, up 145.67% year-over-year; the trailing twelve-month figure through Dec 2010 was $2.8 billion (up 145.67% YoY), and the FY2010 annual result was $2.8 billion, up 145.67% from the prior year.
- Convertible Debt was $2.8 billion for Q4 2010 at Gilead Sciences, up from $2.8 billion in the prior quarter.
- Over five years, Convertible Debt peaked at $2.8 billion in Q4 2010 and troughed at $1.1 billion in Q2 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2010 | 2.84 Bn |
| Sep 30, 2010 | 2.82 Bn |
| Mar 31, 2010 | 1.17 Bn |
| Dec 31, 2009 | 1.16 Bn |
| Sep 30, 2009 | 1.14 Bn |
| Jun 30, 2009 | 1.13 Bn |